Projected Earnings Date: 2025-02-11    (Delayed quote data   2025-01-03)
Last
 167.60
Change
 ⇑ +7.00   (+4.36%)
Volume
  1,125,554
Open
 162.65
High
 167.77
Low
 162.03
8EMA (Daily)
 162.04
40EMA (Daily)
 156.94
50EMA (Daily)
 153.96
STO (Daily)
 39.087
MACD Hist (Daily)
 -1.412
8EMA (Weekly)
 159.302
40EMA (Weekly)
 125.25
50EMA (Weekly)
 118.21
STO (Weekly)
 83.067
MACD Hist (Weekly)
 3.240
Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services includes Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic, or a patient for the test upon delivery of the test result.
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com